deCODE genetics
  • HOME
  • COMPANY
    • ABOUT deCODE
    • MANAGEMENT
    • POLICIES
    • MEDIA RESOURCES
  • SCIENCE
  • PUBLICATIONS
  • NEWS
  • CAREERS
  • CONTACT
  • icelandic
Select Page

deCODE Discovers Gene Variant that Confers Risk of Prostate Cancer and Protects Against Type 2 Diabetes

Jul 1, 2007 | NEWS

In a paper published today, a team of scientists from deCODE genetics (Nasdaq:DCGN) and academic colleagues from Europe and the United States report the discovery of two single letter variations (SNPs) on chromosome 17 associated with increased risk of prostate...

deCODE Discovers a Variation in the Sequence of the Genome Conferring Risk of Atrial Fibrillation Launches deCODE AF™, A Test for the Risk Variant Aimed at the Prevention of Stroke

Jul 1, 2007 | NEWS

A paper published today in the journal Nature describes the discovery by scientists at deCODE genetics (Nasdaq:DCGN), in collaboration with academic colleagues in Iceland, the United States, Sweden and China, of two common single-letter variations in the genome (SNPs)...

Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R &D Event

Jun 25, 2007 | NEWS

Recent clinical studies support the development of DG041 as an effective anti-platelet that does not increase bleeding risk deCODE genetics (Nasdaq:DCGN) today announced progress in the development of DG041, the company’s Phase II developmental compound for the...

deCODE Discovers Common Genetic Variants Linked to Increased Risk of Breast Cancer

May 27, 2007 | NEWS

In a paper published today, a team of scientists from deCODE genetics (Nasdaq:DCGN) and academic colleagues from Europe and the United States report the discovery of two novel and very common genetic variants linked to susceptibility to breast cancer. The variants are...

deCODE Identifies Novel Genetic Variant Associated with Increased Risk of Heart Attack

May 3, 2007 | NEWS

Scientists at deCODE genetics (Nasdaq:DCGN) and academic colleagues from the United States today report the discovery of a common genetic variant that confers increased risk of myocardial infarction (MI), or heart attack. The variant, a SNP (a single-letter variant in...

deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack

May 1, 2007 | NEWS

deCODE genetics (Nasdaq:DCGN) today announced positive top-line results from its Phase I multiple dose clinical trial of DG051, which the company is developing for the prevention of heart attack. In the study, a randomized, double-blind, multi-dose, ascending dose,...
« Older Entries
Next Entries »

MORE ABOUT DECODE

  • MANAGEMENT
  • POLICIES
  • CAREERS
  • AVAILABLE POSITIONS
  • CONTACT
  • NEWS

ABOUT deCODE

  • HOME
  • COMPANY
    • ABOUT deCODE
    • MANAGEMENT
    • POLICIES
    • MEDIA RESOURCES
  • SCIENCE
  • PUBLICATIONS
  • NEWS
  • CAREERS
  • CONTACT
  • icelandic

MANAGEMENT

  • MANAGEMENT
  • POLICIES
  • CAREERS
  • AVAILABLE POSITIONS
  • CONTACT
  • NEWS

LATEST NEWS

  • Genetic Risk Signal in Lupus Identified Through a Distinctive Dataset
  • Amgen deCODE Genetics Takes Part in Its First Mission Week in Iceland

ADDRESS

deCODE genetics
Sturlugata 8 | 101 Reykjavik
Iceland
Phone +354 570 1900

deCODE genetics | Sturlugata 8 | 101 Reykjavik | Iceland | phone +354 570 1900